桡骨远端骨折后骨质疏松评估与治疗的临床角色和时机:范围综述
该范围综述纳入250篇报告,梳理桡骨远端骨折后骨质疏松评估与治疗的证据。观察性研究显示治疗后后续骨折减少,但无随机对照试验,正常骨密度患者研究不足。DXA和FRAX可辅助个体化决策但不应延迟必要治疗。
要点
- 脆性桡骨远端骨折应启动二级预防、继发性病因评估和适时治疗。
- DXA检测率中位数26%,治疗启动率中位数22%,存在巨大 care gap。
- 无随机试验直接比较早期与延迟治疗对后续骨折的影响。
核心结论
- 脆性桡骨远端骨折需及时二级预防、评估继发性病因并给予适时治疗。
- 观察性关联不能确立因果治疗效应,最佳时机和正常骨密度患者的获益尚未解决。
研究设计与样本
- 遵循JBI范围综述方法并按PRISMA-ScR报告,前瞻性注册于OSF。
- 检索PubMed、OpenAlex、Europe PMC、Embase、Cochrane系统评价数据库、KoreaMed和CiNii,日期为2026年5月4日。
- 纳入≥50岁成人桡骨远端骨折或腕部脆性骨折,共250篇报告(2008-2026)。
- 采用双大语言模型筛选、双作者独立审核和源验证图表,描述性综合未合并数据。
主要发现
- 证据涉及基于骨密度的风险与选择(103篇)、care gap(65篇)、预后(40篇)和治疗(42篇)。
- DXA检测率中位数为26%,治疗启动率中位数为22%。
- 估计值异质未合并,无研究直接比较早期与延迟治疗起始对后续骨折的影响。
- 6篇报告聚焦正常骨密度,但无亚组特异性骨折结局估计。
关键数值与推荐
- DXA和FRAX可辅助个体化决策,但不应延迟有指征的治疗。
临床怎么用
- 对≥50岁桡骨远端脆性骨折患者,应及时评估继发性病因并启动有指征的骨质疏松治疗。
- 可使用DXA和FRAX辅助个体化决策,但不应因等待检查而延迟必要治疗。
局限性
- 无随机桡骨远端骨折特异性试验,观察性关联不能确立因果治疗效应。
- 正常骨密度患者研究不足,最佳治疗时机和该人群获益未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Distal radius fracture is an early fragility fracture, yet evidence guiding osteoporosis treatment afterward is unclear. In this scoping review of 250 reports, post-fracture osteoporosis care was associated with fewer subsequent fractures in observational studies, but no randomized distal radius fracture-specific trial exists and normal-bone-mineral-density patients remain understudied. PURPOSE: To map the extent, range, and nature of evidence on the clinical role and timing of osteoporosis evaluation and treatment after distal radius fracture (DRF). METHODS: We conducted a JBI-guided scoping review reported per PRISMA-ScR (prospectively registered on OSF). PubMed, OpenAlex, Europe PMC, Embase, the Cochrane Database of Systematic Reviews, KoreaMed, and CiNii were searched on 4 May 2026 for adults aged ≥50 years with DRF or wrist fragility fracture. Records underwent dual large language model screening, independently audited in duplicate by two authors, and source-verified charting, synthesized descriptively without pooling. RESULTS: Across 250 reports (2008-2026), evidence addressed BMD-based risk and selection (103), the care gap (65), prognosis (40), and treatment (42). Median DXA testing and treatment-initiation rates were 26% and 22%. Eleven observational reports linked treatment or structured care to fracture outcomes; a separate economic model projected outcomes. Estimates were heterogeneous and not pooled. No included study directly compared early versus delayed treatment initiation after DRF with subsequent fracture as the outcome. Six reports focused on normal BMD; none estimated subgroup-specific fracture outcomes. CONCLUSION: A fragility DRF warrants prompt secondary prevention, assessment for secondary causes, and timely indicated treatment. DXA and FRAX can inform individualized decisions but should not delay indicated care. Observational associations do not establish a causal treatment effect; optimal timing and benefit in normal-BMD patients remain unresolved.
引用
- Kwon, Cho, Chae, et al. Clinical role and timing of osteoporosis evaluation and treatment after distal radius fracture: a scoping review. Osteoporos Int. 2026. PMID: 42946792. doi:10.1007/s00198-026-08296-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。